ImPact Biotech is an advanced clinical-stage oncology company focused on developing and commercializing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is being evaluated in a pivotal Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (UTUC), with earlier-stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). The company announced an investment commitment of €13.5M from the European Innovation Council’s Accelerator program, comprising a €2.5M grant and up to €11M in conditional equity. ImPact plans to use the proceeds to advance the ongoing Phase 3 ENLIGHTED trial and to support development across its VTP program. The company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operates in the EU, Israel, and the US; the press release is dated from Tel Aviv, Israel.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2024